RxDoctor Payments Data

Peggy Toliver-Dingle, MD

Internal Medicine · Columbia, SCNPI 1477545325

Payments from drug & device makers

$5,991in general payments, 2019–2025

Across 303 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$723
  • Lilly USA, LLC$578
  • AbbVie$558
  • Boehringer Ingelheim$350
  • Pfizer$299
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$5,76496%
  • Education$1112%
  • Other$1162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,991 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$107,281
Medicare patients
225
Services billed
2,408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$62,679
FarxigaDapagliflozin Propanediol48$49,755
RybelsusSemaglutide31$48,175
TradjentaLinagliptin41$43,053
EliquisApixaban37$35,154
JardianceEmpagliflozin20$32,277
MounjaroTirzepatide26$28,260
TrulicityDulaglutide22$26,145
Soliqua 100-33Insulin Glargine/Lixisenatide17$22,775
XareltoRivaroxaban16$19,303
KerendiaFinerenone12$11,363
JanumetSitagliptin Phos/Metformin Hcl11$11,021
MyrbetriqMirabegron14$9,503
ArexvyRsvpref3 Antigen/As01e/Pf30$9,232
Aimovig AutoinjectorErenumab-Aooe12$8,600

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$723$110,85493 claims
Boehringer IngelheimTradjenta, Jardiance$350$75,33061 claims
Lilly USA, LLCMounjaro, Trulicity$578$54,40548 claims
AstraZenecaFarxiga$1,009$49,75548 claims
PfizerEliquis$299$35,15437 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$153$22,77517 claims
Johnson & JohnsonXarelto$135$19,30316 claims
BayerKerendia$173$11,36312 claims
MerckJanumet$34$11,02111 claims
Astellas Pharma US IncMyrbetriq$77$9,50314 claims
GSKArexvy$13$9,23230 claims
Esperion Therapeutics, Inc.Nexletol$69$6,13314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →